SAT0110 Efficacy and Safety of Pateclizumab (Anti-Lymphotoxin-Alpha) in Dmard-Ir Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Head-To-Head Phase 2 Study with Adalimumab

Background Pateclizumab (formerly MLTA3698A), a novel humanized IgG1 antibody against soluble and membrane isoforms of lymphotoxin-alpha, is being investigated as a targeted therapy for rheumatoid arthritis (RA). Objectives To compare the efficacy and safety of subcutaneous Pateclizumab (PTZ) vs pla...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A617-A618
Hauptverfasser:	Kennedy, W., Horn, P., Su, Z., Basu, K., Herman, A., Song, A., Townsend, M., Xiao, J., Grogan, J., Derby, M., Simon-Campos, J. A., Davis, J.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!